When was Alkahest founded?

Alkahest was founded in 2014 and raised its 1st funding round within a year of its incorporation.

Where is Alkahest located?

Alkahest is headquartered in San Carlos, United States.

How many employees does Alkahest have?

As of Aug 31, 2026, the latest employee count at Alkahest is 33.

Is Alkahest a funded company?

Alkahest is a funded company, having raised a total of $41M across 2 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Aug 01, 2014.

When was the latest funding round of Alkahest?

Alkahest's latest funding was a $***** Series A round on Mar 04, 2015, with participation from 1 investor.

Where does Alkahest rank among its competitors?

Alkahest ranks 254th amongst 764 active competitors, of which 275 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Evommune, which secured $125M in Feb, 2026.

Who are the top competitors of Alkahest?

Alkahest's top competitors include Denali Therapeutics, Fulcrum Therapeutics and Annexon. Among them, Evommune secured the most recent funding round in February, 2026.

Alkahest - 2026 Company Profile, Funding & Competitors

Q: Is Alkahest an acquired company?

Alkahest got acquired by Grifols on Sep 07, 2020.

Company Details

Plasma-based therapies leveraging AI for personalized medicine and disease solutions. This research and drug discovery company mines plasma knowledge to develop transformative therapies. Integrating advanced technology like artificial intelligence and multiomics analysis with plasma protein expertise, they aim to understand the evolving protein network's influence on human biology. By leveraging a vast collection of plasma samples and real-world health data, they target diseases, seeking early biomarkers for prediction, diagnosis, and treatment. Their work contributes to personalized medicine by identifying alterations in plasma proteins linked to various disease states, offering potential solutions for unmet medical needs.

Website: www.alkahest.com/
Social

Key Metrics

Founded Year

2014

Location

San Carlos, United States

Stage

Acquired

Total Funding

$41M in 2 rounds

Latest Funding Round

Series A, Mar 04, 2015, $*****

Investors

Grifols & 2 more

Ranked

254^th among 764 active competitors

Employee Count

33 as on Aug 31, 2026

Similar Companies

Denali Therapeutics & 937 more

Exit Details

Acquired by Grifols (Sep 07, 2020)

View Alkahest's full profile

Alkahest is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Alkahest, Inc. CIN: 464535383 , United States, Active	Dec 31, 1999	-	82 (As on Dec 31, 2023)	-
Alkahest, Inc. CIN: 5459691 , United States, Active		-	94 (As on Dec 31, 2021)	-

Alkahest got acquired by Grifols on Sep 07, 2020 at an acquisition amount of $*****.

Click here to take a look at Alkahest's acquisition in detail

Alkahest has raised a total funding of $41M over 2 rounds. Its first funding round was on Aug 01, 2014. Its latest funding round was a Series A round on Mar 04, 2015 for $*****. 1 investor participated in its latest round. Alkahest has 3 institutional investors.

Here is the list of recent funding rounds of Alkahest:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 04, 2015	5041187	Series A	4264923	9013892	1929858	3366861
Aug 01, 2014	9291145	Seed	3800656	2798049	5792266	1772797

Access funding benchmarks and valuations. Sign up today!

View details of Alkahest's funding rounds and investors

Alkahest's employee count trend

Alkahest has 33 employees as of Aug 26. Here is Alkahest's employee count trend over the years:

Uncover Alkahest's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Alkahest include Denali Therapeutics, Fulcrum Therapeutics and Annexon. Here is the list of Top 10 competitors of Alkahest, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Denali Therapeutics 2015, San Francisco (United States), Public	Developer of therapies to treat neurodegenerative diseases	$347M	Foresite Capital, Baillie Gifford & 10 others	72/100
2nd	Fulcrum Therapeutics 2015, Cambridge (United States), Public	Developing small molecules for control mechanisms and genes regulation for the treatment of rare diseases	$115M	Foresite Capital, Google Ventures & 15 others	70/100
3rd	Annexon 2011, San Francisco (United States), Public	Developer of antibodies to treat complement-mediated neurodegenerative diseases	$256M	Redmile Group, Bain Capital & 17 others	67/100
4th	Regenxbio 2008, Rockville (United States), Public	Developer of AAV Gene Therapy for rare genetic diseases	$108M	Brookside Capital, Venrock & 15 others	67/100
5th	Upstream Bio 2021, Waltham (United States), Public	Developer of therapeutics for allergic and inflammatory diseases	$400M	Venrock, Enavate Sciences & 11 others	67/100
6th	Odyssey 2018, Cambridge (United States), Public	Developer of immunotherapeutics for immunological and cancer diseases	$717M	Orbimed, Ascenta Capital & 29 others	66/100
7th	Septerna 2020, San Bruno (United States), Public	Developer of GPCR drug discovery platform for multiple diseases	$250M	RA Capital Management, Third Rock Ventures ... & 14 others	66/100
8th	Ventyx Biosciences 2018, Encinitas (United States), Acquired	Developer of therapeutics to treat autoimmune diseases	$165M	VenBio, Logos Capital & 13 others	66/100
9th	Evommune 2020, Sacramento (United States), Public	Developer of therapeutic options for chronic inflammatory disorders	$276M	Pivotal bioVenture Partners, RA Capital Management ... & 18 others	66/100
10th	Alector 2013, San Francisco (United States), Public	Developing immuno-modulatory therapies for dementia and other neurodegenerative disorders	$215M	AbbVie, The Dementia Discovery Fund & 20 others	65/100
254th	Alkahest 2014, San Carlos (United States), Acquired	Plasma-based therapies leveraging AI for personalized medicine and disease solutions	$41M	Nan Fung Life Sciences, Grifols & 1 others	39/100